Targovax ASA ( (GB:0RIS) ) has issued an update.
Circio Holding ASA has completed a share capital increase following the conversion of convertible bonds by Atlas Special Opportunities, LLC, raising their share capital to NOK 52,486,542.60. This development supports Circio’s ongoing efforts in pioneering RNA technology and cancer vaccine development, potentially strengthening their market position in nucleic acid and viral therapeutics.
More about Targovax ASA
Circio Holding ASA is a biotechnology company specializing in the development of circular RNA vector expression technology for nucleic acid medicine. Their proprietary circVec platform enhances protein expression significantly compared to traditional mRNA systems and is applicable in genetic medicine, cell therapy, and chronic disease. Circio is also advancing a pan-RAS cancer vaccine, TG01, targeting KRAS mutations, with ongoing clinical trials in the USA and Norway.
YTD Price Performance: -92.47%
Average Trading Volume: 19,930
Technical Sentiment Signal: Buy
Current Market Cap: NOK72.95M
Learn more about 0RIS stock on TipRanks’ Stock Analysis page.